Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Metadata
Title
Plasma thrombomodulin levels in patients with Behçet's disease
Authors
Nurşen Düzgün
Ergin Ayaşlioğlu
Hüseyin Tutkak
Mehmet Şahin
Olcay Aydintuğ
Ümit Ölmez
Publication date
01-05-2003
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 3/2003
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-002-0258-z

Other articles of this Issue 3/2003

Rheumatology International 3/2003 Go to the issue

Original Article

Functional disability and quality of life in patients with ankylosing spondylitis

Original Article

Ex vivo apoptosis, CD95 and CD28 expression in T cells of children with juvenile idiopathic arthritis

Case Report

Peripheral T cell lymphoma-associated hemophagocytic syndrome in a patient with human adjuvant disease

Letter to the Editor

Juvenile chronic arthritis in a monozygotic twin couple

Original Article

The biallelic variable number of tandem repeats of the tumor necrosis factor receptor 2 promoter in systemic lupus erythematosus

Original Article

Polymorphism of the β3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits